hydroxyurea has been researched along with Thrombocythemia in 122 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aims of this study were (1) to detect involvement of N- and K-ras mutations in codons 12 and 13 in the pathogenesis of the chronic and blastic phases of PV and ET, (2) to study the occurrence of microsatellite instability (MSI) in chromosomes 5 and 7 during the chronic phase and blastic transformation of the disease, and (3) to examine the incidence of leukemia in patients treated with hydroxyurea (HU)." | 9.10 | Leukemogenic risk of hydroxyurea therapy as a single agent in polycythemia vera and essential thrombocythemia: N- and K-ras mutations and microsatellite instability in chromosomes 5 and 7 in 69 patients. ( Loukopoulos, D; Madzourani, M; Mavrogianni, D; Meletis, J; Michali, E; Pangalis, G; Terpos, E; Vaiopoulos, G; Viniou, N; Yataganas, X, 2002) |
| "Hydroxyurea is effective in preventing thrombosis in high-risk patients with essential thrombocythemia." | 9.08 | Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. ( Barbui, T; Cortelazzo, S; Finazzi, G; Galli, M; Rodeghiero, F; Ruggeri, M; Vestri, O, 1995) |
| "Hydroxyurea (HU) is effective in controlling thrombocytosis while reducing the risk of thrombosis in essential thrombocythemia (ET), polycythemia vera (PV) and myelofibrosis (MF)." | 8.83 | Leg ulcers in elderly on hydroxyurea: a single center experience in Ph- myeloproliferative disorders and review of literature. ( Fabris, F; Luzzatto, G; Randi, ML; Ruzzon, E; Scandellari, R; Tezza, F, 2006) |
| "We present a case of oral ulceration in a patient with essential thrombocythaemia, that proved to be secondary to treatment with hydroxyurea." | 8.80 | Oral ulcers caused by hydroxyurea. ( Lindsey, L; Paleri, V, 2000) |
| "The mechanism of hydroxyurea-induced fever remains unclear." | 8.79 | Hydroxyurea-induced fever: case report and review of the literature. ( Lossos, IS; Matzner, Y, 1995) |
| "The development of painful leg ulcers in the ankle area is a rare and only partially described complication in patients receiving high-dose, long-term hydroxyurea treatment for myeloproliferative diseases." | 7.74 | Hydroxyurea-induced leg ulcers treated with a protease-modulating matrix. ( Dini, V; Romanelli, M; Romanelli, P, 2007) |
| "The efficacy of hydroxyurea (HU) in myeloproliferative disorders is well documented." | 7.73 | Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders. ( Fabris, F; Girolami, A; Luzzatto, G; Randi, ML; Ruzzon, E; Tezza, F, 2005) |
| "Hydroxyurea (HU) is usually a well-tolerated antineoplastic agent, which is commonly used in the treatment of myeloproliferative disorders." | 7.71 | [Hydroxyurea-induced leg ulcers in patients with chronic myeloproliferative disorders]. ( Olesen, LH; Pedersen, BB, 2001) |
| "The association of lower leg ulcer development and hydroxyurea therapy in patients with myeloproliferative disorders has been reported previously." | 7.71 | Aggressive, extensive, vasculitic leg ulceration associated with hydroxyurea therapy and a fatal outcome. ( Kirby, B; Stewart, EJ; Young, HS, 2001) |
| "We report on three patients who developed fever after starting treatment with the anti-neoplastic agent, hydroxyurea." | 7.69 | Fever attributed to the use of hydroxyurea. ( Feenstra, J; in 't Veld, BA; Runhaar, EA; Slappendel, AM; Stricker, BH; van Aken, J; Veen, C, 1997) |
| "From 1981 to 1995, we diagnosed, followed and treated at our institution fifty-eight cases of essential thrombocythemia (ET), using hydroxyurea (HU) as first-line therapy in these patients." | 7.69 | Is treatment with hydroxyurea leukemogenic in patients with essential thrombocythemia? An analysis of three new cases of leukaemic transformation and review of the literature. ( Bordessoule, D; Brigaudeau, C; Desangles, F; Fermeaux, V; Liozon, E; Praloran, V; Trimoreau, F, 1997) |
| "We report four cases of cutaneous lower leg ulcers associated with hydroxyurea treatment for myeloproliferative disorders." | 7.68 | Hydroxyurea and lower leg ulcers. ( Margolis, DJ; Nguyen, TV, 1993) |
| "The effect of hydroxyurea in 35 patients with chronic granulocytic leukemia (CGL), who either had entered an accelerated phase of the disease or had experienced excessive myelosuppression following alkylating agents, was studied." | 7.65 | Hydroxyurea in the management of the hematologic complications of chronic granulocytic leukemia. ( Cannellos, GP; Schwartz, JH, 1975) |
| "Hydroxyurea is an antineoplastic agent commonly used to treat essential thrombocytosis." | 5.40 | Melanonychia and mucocutaneous hyperpigmentation from hydroxyurea use for the treatment of essential thrombocytosis. ( Gupta, A; Karanth, SS; Prabhu, M, 2014) |
| "Hydroxyurea is a common cancer chemotherapy agent that inhibits ribonucleotide reductase, an enzyme essential to DNA synthesis." | 5.30 | Hydroxyurea-induced leg ulcers: is macroerythrocytosis a pathogenic factor? ( García-Aranda, JM; Moreno, JC; Vélez, A, 1999) |
| " The aims of this study were (1) to detect involvement of N- and K-ras mutations in codons 12 and 13 in the pathogenesis of the chronic and blastic phases of PV and ET, (2) to study the occurrence of microsatellite instability (MSI) in chromosomes 5 and 7 during the chronic phase and blastic transformation of the disease, and (3) to examine the incidence of leukemia in patients treated with hydroxyurea (HU)." | 5.10 | Leukemogenic risk of hydroxyurea therapy as a single agent in polycythemia vera and essential thrombocythemia: N- and K-ras mutations and microsatellite instability in chromosomes 5 and 7 in 69 patients. ( Loukopoulos, D; Madzourani, M; Mavrogianni, D; Meletis, J; Michali, E; Pangalis, G; Terpos, E; Vaiopoulos, G; Viniou, N; Yataganas, X, 2002) |
| "Hydroxyurea is effective in preventing thrombosis in high-risk patients with essential thrombocythemia." | 5.08 | Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. ( Barbui, T; Cortelazzo, S; Finazzi, G; Galli, M; Rodeghiero, F; Ruggeri, M; Vestri, O, 1995) |
| "Hydroxyurea (HU) is effective in controlling thrombocytosis while reducing the risk of thrombosis in essential thrombocythemia (ET), polycythemia vera (PV) and myelofibrosis (MF)." | 4.83 | Leg ulcers in elderly on hydroxyurea: a single center experience in Ph- myeloproliferative disorders and review of literature. ( Fabris, F; Luzzatto, G; Randi, ML; Ruzzon, E; Scandellari, R; Tezza, F, 2006) |
| " In this regard, a controlled clinical trial has previously demonstrated the efficacy of hydroxyurea in reducing the risk of thrombosis in high-risk patients with essential thrombocythemia (ET)." | 4.82 | A critical review of anagrelide therapy in essential thrombocythemia and related disorders. ( Dingli, D; Tefferi, A, 2005) |
| "We present a case of oral ulceration in a patient with essential thrombocythaemia, that proved to be secondary to treatment with hydroxyurea." | 4.80 | Oral ulcers caused by hydroxyurea. ( Lindsey, L; Paleri, V, 2000) |
| "Leg ulcers are a relatively frequent problem in patients with myeloproliferative disorders under treatment with hydroxyurea (HU)." | 4.80 | Leg ulcers in patients with myeloproliferative disorders: disease- or treatment-related? ( Bader, U; Banyai, M; Böni, R; Burg, G; Hafner, J, 2000) |
| "The mechanism of hydroxyurea-induced fever remains unclear." | 4.79 | Hydroxyurea-induced fever: case report and review of the literature. ( Lossos, IS; Matzner, Y, 1995) |
| " Treatment selection is based on a patient's age and a history of thrombosis in patients with low-risk PV treated with therapeutic phlebotomy and aspirin alone, whereas cytoreductive therapy with either hydroxyurea or interferon alfa (IFN-α) is added for high-risk disease." | 4.31 | Moving toward disease modification in polycythemia vera. ( Bewersdorf, JP; Bose, P; How, J; Masarova, L; Mascarenhas, J; Pemmaraju, N; Rampal, RK, 2023) |
| "The development of painful leg ulcers in the ankle area is a rare and only partially described complication in patients receiving high-dose, long-term hydroxyurea treatment for myeloproliferative diseases." | 3.74 | Hydroxyurea-induced leg ulcers treated with a protease-modulating matrix. ( Dini, V; Romanelli, M; Romanelli, P, 2007) |
| "The efficacy of hydroxyurea (HU) in myeloproliferative disorders is well documented." | 3.73 | Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders. ( Fabris, F; Girolami, A; Luzzatto, G; Randi, ML; Ruzzon, E; Tezza, F, 2005) |
| " The study group comprised hydroxyurea treated and untreated patients with essential thrombocytosis (ET) or polycythemia vera (PV)." | 3.71 | Replication status in leukocytes of treated and untreated patients with polycythemia vera and essential thrombocytosis. ( Amiel, A; Elis, A; Ellis, M; Fejgin, MD; Gaber, E; Herishano, Y; Lishner, M; Maimon, O, 2002) |
| "The association of lower leg ulcer development and hydroxyurea therapy in patients with myeloproliferative disorders has been reported previously." | 3.71 | Aggressive, extensive, vasculitic leg ulceration associated with hydroxyurea therapy and a fatal outcome. ( Kirby, B; Stewart, EJ; Young, HS, 2001) |
| "Hydroxyurea (HU) is usually a well-tolerated antineoplastic agent, which is commonly used in the treatment of myeloproliferative disorders." | 3.71 | [Hydroxyurea-induced leg ulcers in patients with chronic myeloproliferative disorders]. ( Olesen, LH; Pedersen, BB, 2001) |
| "Factors that influence the choice of anagrelide, hydroxyurea, or interferon-alfa (IFN-alpha) for treatment of essential thrombocythemia include efficacy, toxicity, and cost." | 3.71 | Cost-effectiveness considerations in the treatment of essential thrombocythemia. ( Adams, J; Bennett, CL; Dave, S; Golub, R, 2002) |
| "From 1981 to 1995, we diagnosed, followed and treated at our institution fifty-eight cases of essential thrombocythemia (ET), using hydroxyurea (HU) as first-line therapy in these patients." | 3.69 | Is treatment with hydroxyurea leukemogenic in patients with essential thrombocythemia? An analysis of three new cases of leukaemic transformation and review of the literature. ( Bordessoule, D; Brigaudeau, C; Desangles, F; Fermeaux, V; Liozon, E; Praloran, V; Trimoreau, F, 1997) |
| " A care of pregnancy complicated by essential thrombocythemia treated with aspirin, antiaggregating agent, throughout pregnancy and with hydroxyurea, a platelet lowering drug is reported." | 3.69 | [Essential thrombocythemia in pregnancy. A case report and general considerations]. ( Catalano, D; Dell'Isola, A; Di Rosa, G, 1997) |
| "We report on three patients who developed fever after starting treatment with the anti-neoplastic agent, hydroxyurea." | 3.69 | Fever attributed to the use of hydroxyurea. ( Feenstra, J; in 't Veld, BA; Runhaar, EA; Slappendel, AM; Stricker, BH; van Aken, J; Veen, C, 1997) |
| "We report four cases of cutaneous lower leg ulcers associated with hydroxyurea treatment for myeloproliferative disorders." | 3.68 | Hydroxyurea and lower leg ulcers. ( Margolis, DJ; Nguyen, TV, 1993) |
| "The effect of hydroxyurea in 35 patients with chronic granulocytic leukemia (CGL), who either had entered an accelerated phase of the disease or had experienced excessive myelosuppression following alkylating agents, was studied." | 3.65 | Hydroxyurea in the management of the hematologic complications of chronic granulocytic leukemia. ( Cannellos, GP; Schwartz, JH, 1975) |
| "Secondary thrombocytosis is a frequent secondary finding in childhood infection and inflammation." | 2.72 | Thrombocytosis in children and adolescents-classification, diagnostic approach, and clinical management. ( Cario, H; Duffert, CM; Knöfler, R; Kulozik, AE; Stockklausner, C; Streif, W, 2021) |
| "It is concluded that leukocytosis and thrombocytosis are seen in most patients with myelofibrosis during treatment with imatinib." | 2.71 | Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis. ( Birgens, H; Bjerrum, OW; Clausen, NT; Hansen, PB; Hasselbalch, HC; Jensen, BA; Ralfkiaer, E; Therkildsen, MH, 2003) |
| "Thrombocytosis was not found to be a prognostic factor in patients with positive pelvic nodes." | 2.69 | The significance of thrombocytosis in patients with locally advanced cervical carcinoma: a Gynecologic Oncology Group study. ( Anderson, LL; Donohue, KA; Heller, PB; Hernandez, E; Stehman, FB, 2000) |
| "Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms, respectively characterized by erythrocytosis and thrombocytosis." | 2.52 | Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. ( Barbui, T; Tefferi, A, 2015) |
| "Primary thrombocytosis is extremely rare in childhood, mostly diagnosed at the beginning of the second decade of life." | 2.43 | Primary and secondary thrombocytosis in childhood. ( Dame, C; Sutor, AH, 2005) |
| "The association of chronic lymphocytic leukemia (CLL) with essential thrombocythemia (ET) is an extremely rare event and until now 3 patients with such coexistence have been reported in the literature." | 2.42 | Coexistence of chronic lymphocytic leukemia and essential thrombocythemia. ( Bartkowiak, J; Góra-Tybor, J; Kordek, R; Korycka, A; Polliack, A; Robak, T; Urbańska-Ryś, H; Wawrzyniak, E, 2003) |
| "Phlebotomy is the mainstay of treatment for polycythemia vera." | 2.41 | Diagnosis and treatment of thrombocythemia in myeloproliferative disorders. ( Gilbert, HS, 2001) |
| "The principal risks of essential thrombocythemia include thrombosis, major hemorrhage, and conversion to leukemia or myelofibrosis." | 2.41 | Therapeutic options for essential thrombocythemia and polycythemia vera. ( Solberg, LA, 2002) |
| "Polycythemia vera (PV) and essential thrombocythemia (ET) are chronic disorders for which there are no medical cures." | 2.41 | Other secondary sequelae of treatments for myeloproliferative disorders. ( Gilbert, HS, 2002) |
| "By contrast, in thrombocythemia, whether primary or associated with other myeloproliferative lesions, significant thrombohemorrhagic events occur." | 2.38 | The clinical spectrum of thrombocytosis and thrombocythemia. ( Frenkel, EP, 1991) |
| "Hydroxyurea treatment was initiated, leading to a gradual decrease in platelet count." | 1.62 | Differential diagnostic and treatment difficulties in a patient with acquired von Willebrand syndrome. ( Bedekovics, J; Bereczky, Z; Illés, Á; Kracskó, B; Magyari, F; Schlammadinger, Á, 2021) |
| "Polycythemia Vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms respectively characterized by erythrocytosis and thrombocytosis; other disease features include leukocytosis, splenomegaly, thrombosis, bleeding, microcirculatory symptoms, pruritus, and risk of leukemic or fibrotic transformation." | 1.46 | Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management. ( Barbui, T; Tefferi, A, 2017) |
| "Non-melanoma skin cancers were reported in 51 patients (27%)." | 1.40 | Cyclical thrombocytosis, acquired von Willebrand syndrome and aggressive non-melanoma skin cancers are common in patients with Philadelphia-negative myeloproliferative neoplasms treated with hydroxyurea. ( Forsyth, C; Grigg, A; Verner, E, 2014) |
| "Hydroxyurea is an antineoplastic agent commonly used to treat essential thrombocytosis." | 1.40 | Melanonychia and mucocutaneous hyperpigmentation from hydroxyurea use for the treatment of essential thrombocytosis. ( Gupta, A; Karanth, SS; Prabhu, M, 2014) |
| "Hydroxyurea is a cytotoxic agent widely used in the treatment of myeloproliferative disorders." | 1.40 | Hydroxyurea-induced interstitial pneumonitis: case report and review of the literature. ( Angelici, E; Antonaglia, C; Giannelli, V; Internullo, M; Palange, P; Sardo, L; Villani, T, 2014) |
| "female, with essential thrombocythemia, who was admitted to our clinic because of double suicidal ingestion of hydroxycarbamide." | 1.38 | Double, suicidal intoxication with hydroxycarbamide--a case report. ( Kabata, P; Sein Anand, J; Waldman, W, 2012) |
| "The hygroma was associated to thrombocythemia." | 1.35 | Chronic subdural hygroma with thrombocythemia: first case report. ( Kanat, A; Kazdal, H; Yazar, U, 2009) |
| "Mucositis was the main adverse effect of treatment." | 1.34 | Cerebral venous sinus thrombosis associated with essential thrombocytosis in a pediatric patient. ( Arndt, CA; Jensen, AW; Tefferi, A, 2007) |
| "Philadelphia-chromosome positive thrombocythemia without features of chronic myeloid leukemia in peripheral blood has been described in adults." | 1.33 | Philadelphia-chromosome positive thrombocythemia in a child. ( Chatterjee, T; Choudhry, DR; Choudhry, VP; Dixit, A; Kumar, R; Mahapatra, M; Mishra, P; Sazawal, S; Tyagi, S, 2005) |
| "She developed severe hypersensitivity pneumonitis soon after the drug was initiated and required intubation and mechanical ventilation." | 1.32 | Severe hypersensitivity pneumonitis associated with anagrelide. ( Brink, DJ; Mazer, MA; Raghavan, M, 2003) |
| "Nine cases with a pneumonitis (alveolitis or interstitial lung disease) have been described so far." | 1.32 | [Hydroxyurea-induced pneumonitis]. ( Schwonzen, M; Spangenberger, H; Spengler, M, 2003) |
| " This is an adverse effect of hydroxyurea that is not infrequently seen but is difficult to recognise." | 1.32 | [Ulcers on the legs and feet: a seldom recognised side effect of hydroxyurea]. ( Janssen, JJ; Ossenkoppele, GJ, 2003) |
| "Bone marrow examinations reveal chromosomal abnormalities in 15-43% of PV patients and 5% of ET patients, but no specific recurring abnormality has been found to date." | 1.31 | Comparative genomic hybridization in polycythemia vera and essential thrombocytosis patients. ( Amiel, A; Bomstein, Y; Fejgin, MD; Gaber, E; Herishanu, Y; Kitay-Cohen, Y; Lishner, M, 2001) |
| "It has been reported that trisomy 14 is associated with myeloid malignancies, but a case with increased platelet count has also been reported." | 1.31 | Trisomy 14 with thrombocytosis and monocytosis. ( Kaya, H; Maeno, K; Matsuda, T; Nakamura, S; Ohtake, S; Okafuji, K; Tanaka, N; Terasaki, Y, 2000) |
| "Thrombocytosis is a common clinical condition." | 1.31 | Thrombocytosis--report of a case. ( Pavithran, K; Somarajan, A; Thomas, M, 2000) |
| "Aortic thrombus formation is rare in the patients with essential thrombocytosis (ET); therefore, no guidelines for its management have been established." | 1.31 | Medical management of a large aortic thrombus in a young woman with essential thrombocythemia. ( Agha, S; Cleary, JP; Fang, M; Lee, R; Lockridge, L; Mazur, EM, 2001) |
| "The clinical importance of finding the Philadelphia chromosome in patients who seem to have ET is in assessing prognosis." | 1.31 | BCR-ABL positive essential thrombocythaemia: a variant of chronic myelogerous leukaemia or a distinct clinical entity: a special case report. ( Cheong, SK; Fadilah, SA, 2000) |
| "Hydroxyurea is a common cancer chemotherapy agent that inhibits ribonucleotide reductase, an enzyme essential to DNA synthesis." | 1.30 | Hydroxyurea-induced leg ulcers: is macroerythrocytosis a pathogenic factor? ( García-Aranda, JM; Moreno, JC; Vélez, A, 1999) |
| "Hydroxyurea is a usually well-tolerated cytostatic agent, but its side effects include cutaneous lesions that appear after several years of maintenance therapy with hydroxyurea." | 1.30 | Early cutaneous lesions secondary to hydroxyurea therapy. ( Calori, R; Faccini, P; Maiolo, AT; Radaelli, F, 1998) |
| "The association of multiple cutaneous cancers and long-term use of hydroxyurea is now being recognized." | 1.30 | Multiple skin cancers associated with hydroxyurea therapy. ( Best, PJ; Petitt, RM, 1998) |
| "Essential thrombocythemia is a myeloproliferative disorder that infrequently evolves into acute leukemia." | 1.29 | Acute lymphoblastic leukemia in a case of essential thrombocythemia. ( Litz, CE; Woronzoff-Dashkoff, KK, 1996) |
| "The 61 observations of primary thrombocythemia described in this report represent approximately 15% of the cases of polycythemia vera recorded by the authors over the same 18-year period." | 1.27 | [Essential thrombocythemia. Clinical, biological study and developmental study of 61 cases]. ( Bauters, F; Demory, JL; Huart, JJ; Jouet, JP; Simon, M, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (9.02) | 18.7374 |
| 1990's | 33 (27.05) | 18.2507 |
| 2000's | 55 (45.08) | 29.6817 |
| 2010's | 17 (13.93) | 24.3611 |
| 2020's | 6 (4.92) | 2.80 |
| Authors | Studies |
|---|---|
| Bewersdorf, JP | 1 |
| How, J | 1 |
| Masarova, L | 1 |
| Bose, P | 1 |
| Pemmaraju, N | 1 |
| Mascarenhas, J | 1 |
| Rampal, RK | 1 |
| Bolaman, AZ | 1 |
| Yavaşoǧlu, İ | 1 |
| Brown, H | 1 |
| Lamrock, E | 1 |
| Boucher, AA | 1 |
| Dong, M | 1 |
| Vinks, AA | 1 |
| Marahatta, A | 1 |
| Howard, TA | 1 |
| Ware, RE | 1 |
| Nathan, JD | 1 |
| Abu-El-Haija, M | 1 |
| Luchtman-Jones, L | 1 |
| Magyari, F | 1 |
| Kracskó, B | 1 |
| Bedekovics, J | 1 |
| Bereczky, Z | 1 |
| Illés, Á | 1 |
| Schlammadinger, Á | 1 |
| Stockklausner, C | 1 |
| Duffert, CM | 1 |
| Cario, H | 1 |
| Knöfler, R | 1 |
| Streif, W | 1 |
| Kulozik, AE | 1 |
| Hwang, JH | 1 |
| Kim, DW | 1 |
| Kim, KS | 1 |
| Lee, SY | 1 |
| Saito, A | 1 |
| Fujisawa, Y | 1 |
| Maruyama, H | 1 |
| Nakamura, Y | 1 |
| Ishitsuka, Y | 1 |
| Watanabe, R | 1 |
| Okiyama, N | 1 |
| Fujimoto, M | 1 |
| Park, SH | 1 |
| Chi, HS | 1 |
| Cho, YU | 1 |
| Jang, S | 1 |
| Park, CJ | 1 |
| Kim, DY | 1 |
| Lee, JH | 1 |
| Lee, KH | 1 |
| Verner, E | 1 |
| Forsyth, C | 1 |
| Grigg, A | 1 |
| Singh, A | 1 |
| Chaudhary, R | 1 |
| Nityanand, S | 1 |
| Karanth, SS | 1 |
| Gupta, A | 1 |
| Prabhu, M | 1 |
| Internullo, M | 1 |
| Giannelli, V | 1 |
| Sardo, L | 1 |
| Antonaglia, C | 1 |
| Villani, T | 1 |
| Angelici, E | 1 |
| Palange, P | 1 |
| Matthews, AG | 1 |
| Wylie, G | 1 |
| Tefferi, A | 4 |
| Barbui, T | 4 |
| Polverelli, N | 1 |
| Catani, L | 1 |
| Vianelli, N | 1 |
| Baccarani, M | 2 |
| Cavo, M | 1 |
| Palandri, F | 1 |
| Birgegård, G | 1 |
| D'adda, M | 1 |
| Micheletti, M | 1 |
| Drera, M | 1 |
| Ferrari, S | 1 |
| Rossi, G | 1 |
| Kanat, A | 1 |
| Yazar, U | 1 |
| Kazdal, H | 1 |
| Martínez-Trillos, A | 1 |
| Gaya, A | 1 |
| Maffioli, M | 1 |
| Arellano-Rodrigo, E | 1 |
| Calvo, X | 1 |
| Díaz-Beyá, M | 1 |
| Cervantes, F | 1 |
| Ziarkiewicz, M | 1 |
| Dwilewicz-Trojaczek, J | 1 |
| Pastwińska, A | 1 |
| Chmarzyńska, E | 1 |
| Paszkowska-Kowalewska, M | 1 |
| Koperski, Ł | 1 |
| Jędrzejczak, WW | 1 |
| Ziarkiewicz-Wróblewska, B | 1 |
| Schleußinger, TM | 1 |
| Dyall-Smith, D | 1 |
| Field, LM | 1 |
| Karimi, M | 1 |
| Haghpanah, S | 1 |
| Bagheri, MH | 1 |
| Bordbar, MR | 1 |
| Pishdad, P | 1 |
| Rachmilewitz, EA | 1 |
| Waldman, W | 1 |
| Kabata, P | 1 |
| Sein Anand, J | 1 |
| Clerico, R | 1 |
| Corsetti, P | 1 |
| Ambrifi, M | 1 |
| Paolino, G | 1 |
| Rossi, MR | 1 |
| Bottoni, U | 1 |
| Calvieri, S | 1 |
| Hong, Y | 1 |
| Erusalimsky, JD | 1 |
| Gabriel, L | 1 |
| de Meester, A | 1 |
| Wollina, U | 1 |
| Raghavan, M | 1 |
| Mazer, MA | 1 |
| Brink, DJ | 1 |
| Janssen, JJ | 1 |
| Ossenkoppele, GJ | 1 |
| Schwonzen, M | 1 |
| Spangenberger, H | 1 |
| Spengler, M | 1 |
| Robak, T | 1 |
| Urbańska-Ryś, H | 1 |
| Góra-Tybor, J | 1 |
| Wawrzyniak, E | 1 |
| Korycka, A | 1 |
| Bartkowiak, J | 1 |
| Kordek, R | 1 |
| Polliack, A | 1 |
| Hasselbalch, HC | 1 |
| Bjerrum, OW | 1 |
| Jensen, BA | 1 |
| Clausen, NT | 1 |
| Hansen, PB | 1 |
| Birgens, H | 1 |
| Therkildsen, MH | 1 |
| Ralfkiaer, E | 1 |
| Schafer, AI | 1 |
| Cheung, MC | 1 |
| Hicks, LK | 1 |
| Pendergrast, J | 1 |
| Silver, RT | 1 |
| Randi, ML | 2 |
| Ruzzon, E | 2 |
| Luzzatto, G | 2 |
| Tezza, F | 2 |
| Girolami, A | 1 |
| Fabris, F | 2 |
| Dame, C | 1 |
| Sutor, AH | 1 |
| Dingli, D | 1 |
| Mishra, P | 1 |
| Mahapatra, M | 1 |
| Kumar, R | 1 |
| Dixit, A | 1 |
| Chatterjee, T | 1 |
| Tyagi, S | 1 |
| Choudhry, DR | 1 |
| Sazawal, S | 1 |
| Choudhry, VP | 1 |
| Chim, CS | 1 |
| Ma, SK | 1 |
| Fruchtman, S | 1 |
| Iyoda, M | 1 |
| Ito, J | 1 |
| Ajiro, Y | 1 |
| Nagai, H | 1 |
| Uchida, J | 1 |
| Honda, H | 1 |
| Kuroki, A | 1 |
| Shibata, T | 1 |
| Kitazawa, K | 1 |
| Sugisaki, T | 1 |
| Papageorgiou, T | 1 |
| Theodoridou, A | 1 |
| Kourti, M | 1 |
| Nikolaidou, S | 1 |
| Athanassiadou, F | 1 |
| Kaloutsi, V | 1 |
| Lankipalli, R | 1 |
| Konkle, B | 1 |
| Mohler, ER | 1 |
| Scandellari, R | 1 |
| Teo, RY | 1 |
| Tan, E | 1 |
| Rappoport, L | 1 |
| Körber, A | 1 |
| Grabbe, S | 1 |
| Dissemond, J | 1 |
| Jensen, AW | 1 |
| Arndt, CA | 1 |
| Wilkins, BS | 1 |
| Erber, WN | 1 |
| Bareford, D | 1 |
| Buck, G | 1 |
| Wheatley, K | 1 |
| East, CL | 1 |
| Paul, B | 1 |
| Harrison, CN | 1 |
| Green, AR | 1 |
| Campbell, PJ | 1 |
| Romanelli, M | 1 |
| Dini, V | 1 |
| Romanelli, P | 1 |
| León-Mateos, A | 1 |
| Zulaica, A | 1 |
| Caeiro, JL | 1 |
| Fabeiro, JM | 1 |
| Calviño, S | 1 |
| Peteiro, C | 1 |
| Toribio, J | 1 |
| Tekin, M | 1 |
| Gökaslan, S | 1 |
| Diker, E | 1 |
| Aydoğdu, S | 1 |
| Simon, M | 1 |
| Jouet, JP | 1 |
| Huart, JJ | 1 |
| Demory, JL | 3 |
| Bauters, F | 3 |
| Mughal, TI | 1 |
| Van Genderen, PJ | 2 |
| Michiels, JJ | 2 |
| Feiner, RH | 1 |
| Ring, T | 1 |
| Zauber, NP | 1 |
| Vlad, LD | 1 |
| Cortelazzo, S | 1 |
| Finazzi, G | 2 |
| Ruggeri, M | 1 |
| Vestri, O | 1 |
| Galli, M | 1 |
| Rodeghiero, F | 1 |
| Lossos, IS | 1 |
| Matzner, Y | 1 |
| Brandt, L | 1 |
| Anderson, H | 1 |
| van der Poel-van de Luytgaarde, SC | 1 |
| van Vliet, HH | 1 |
| Fernandez, H | 1 |
| Nguyen, TV | 1 |
| Margolis, DJ | 1 |
| Baron, BW | 1 |
| Mick, R | 1 |
| Baron, JM | 1 |
| Kwong, YL | 1 |
| Woronzoff-Dashkoff, KK | 1 |
| Litz, CE | 1 |
| Carvajal, S | 1 |
| Zapata, R | 1 |
| Bertín, P | 1 |
| Miquel, JF | 1 |
| Dapling, RB | 1 |
| Snowden, JA | 1 |
| West, J | 1 |
| Talbot, JF | 1 |
| Nelson, ME | 1 |
| Greaves, M | 1 |
| Liozon, E | 1 |
| Brigaudeau, C | 1 |
| Trimoreau, F | 1 |
| Desangles, F | 1 |
| Fermeaux, V | 1 |
| Praloran, V | 1 |
| Bordessoule, D | 2 |
| Dell'Isola, A | 1 |
| Di Rosa, G | 1 |
| Catalano, D | 1 |
| van der Klooster, JM | 1 |
| Sucec, PM | 1 |
| Stiegelis, WF | 1 |
| Hagenbeek, A | 1 |
| in 't Veld, BA | 1 |
| Slappendel, AM | 1 |
| Feenstra, J | 1 |
| Veen, C | 1 |
| van Aken, J | 1 |
| Runhaar, EA | 1 |
| Stricker, BH | 1 |
| Sterkers, Y | 1 |
| Preudhomme, C | 1 |
| Laï, JL | 1 |
| Caulier, MT | 1 |
| Wattel, E | 1 |
| Fenaux, P | 1 |
| Radaelli, F | 1 |
| Calori, R | 1 |
| Faccini, P | 1 |
| Maiolo, AT | 1 |
| Best, PJ | 1 |
| Petitt, RM | 1 |
| Varma, S | 1 |
| Lanigan, SW | 1 |
| Lannemyr, O | 1 |
| Kutti, J | 2 |
| Vélez, A | 1 |
| García-Aranda, JM | 1 |
| Moreno, JC | 1 |
| Cohen, AD | 1 |
| Hallel-Halevy, D | 1 |
| Hatskelzon, L | 1 |
| Peretz, E | 1 |
| Halevy, S | 1 |
| Liu, M | 1 |
| Lee, AG | 1 |
| Rice, L | 1 |
| Lambert, HM | 1 |
| Bader, U | 1 |
| Banyai, M | 1 |
| Böni, R | 1 |
| Burg, G | 1 |
| Hafner, J | 1 |
| Yeh, H | 1 |
| Lichtman, SM | 1 |
| Andréasson, B | 1 |
| Lindstedt, G | 1 |
| Fujimura, K | 1 |
| McLintock, C | 1 |
| Ockelford, PA | 1 |
| Hernandez, E | 1 |
| Donohue, KA | 1 |
| Anderson, LL | 1 |
| Heller, PB | 1 |
| Stehman, FB | 1 |
| Kaya, H | 1 |
| Nakamura, S | 1 |
| Okafuji, K | 1 |
| Terasaki, Y | 1 |
| Maeno, K | 1 |
| Tanaka, N | 1 |
| Ohtake, S | 1 |
| Matsuda, T | 1 |
| Paleri, V | 1 |
| Lindsey, L | 1 |
| Thomas, M | 1 |
| Pavithran, K | 1 |
| Somarajan, A | 1 |
| Fadilah, SA | 1 |
| Cheong, SK | 1 |
| Fang, M | 1 |
| Agha, S | 1 |
| Lockridge, L | 1 |
| Lee, R | 1 |
| Cleary, JP | 1 |
| Mazur, EM | 1 |
| Forkert, R | 1 |
| Ko, Y | 1 |
| Fronhoffs, S | 1 |
| Tschubel, K | 1 |
| Vetter, H | 1 |
| Herishanu, Y | 1 |
| Lishner, M | 2 |
| Bomstein, Y | 1 |
| Kitay-Cohen, Y | 1 |
| Fejgin, MD | 2 |
| Gaber, E | 2 |
| Amiel, A | 2 |
| Gilbert, HS | 2 |
| Young, HS | 1 |
| Kirby, B | 1 |
| Stewart, EJ | 1 |
| Ghotekar, LH | 1 |
| Dutta, TK | 1 |
| Kumarasamy, V | 1 |
| Olesen, LH | 1 |
| Pedersen, BB | 1 |
| Voskaridou, E | 1 |
| Terpos, E | 2 |
| Komninaka, V | 1 |
| Eftyhiadis, E | 1 |
| Mantzourani, M | 1 |
| Loukopoulos, D | 2 |
| Elis, A | 1 |
| Maimon, O | 1 |
| Ellis, M | 1 |
| Herishano, Y | 1 |
| Gyan, E | 1 |
| Darre, S | 1 |
| Jude, B | 1 |
| Cambier, N | 1 |
| Rose, C | 1 |
| Mavrogianni, D | 1 |
| Viniou, N | 1 |
| Michali, E | 1 |
| Meletis, J | 1 |
| Vaiopoulos, G | 1 |
| Madzourani, M | 1 |
| Pangalis, G | 1 |
| Yataganas, X | 1 |
| Solberg, LA | 1 |
| Golub, R | 1 |
| Adams, J | 1 |
| Dave, S | 1 |
| Bennett, CL | 1 |
| Schwartz, JH | 1 |
| Cannellos, GP | 1 |
| MacEwen, EG | 1 |
| Drazner, FH | 1 |
| McClelland, AJ | 1 |
| Wilkins, RJ | 1 |
| Adlakha, A | 1 |
| Bechard, DL | 1 |
| Geer, MR | 1 |
| Frenkel, EP | 1 |
| Ebbe, S | 1 |
| Degen, MA | 1 |
| Feldman, BF | 1 |
| Turrel, JM | 1 |
| Goding, B | 1 |
| Kitchell, B | 1 |
| Mandell, CP | 1 |
| Froom, P | 1 |
| Aghai, E | 1 |
| Kinarty, A | 1 |
| Lahat, N | 1 |
| Tura, S | 1 |
| Mandelli, F | 1 |
| Amadori, S | 1 |
| Cajozzo, A | 1 |
| di Marco, P | 1 |
| Panzacchi, G | 1 |
| Cacciola, E | 1 |
| Musso, R | 1 |
| Alberti, A | 1 |
| Magro, S | 1 |
| Rossi Ferrini, P | 1 |
| Leoni, F | 1 |
| Salti, F | 1 |
| Basetta, E | 1 |
| Monfardini, S | 1 |
| Buonanno, G | 1 |
| Rizzoli, V | 1 |
| Carnevali, C | 1 |
| Lucarelli, G | 1 |
| Porcellini, A | 1 |
| Torlontano, G | 1 |
| Fioritoni, G | 1 |
| Lèques, B | 2 |
| Texier, L | 2 |
| Verdaguer, S | 1 |
| Hoffman-Martinot, R | 1 |
| Paulet, C | 1 |
| Moine, M | 1 |
| Mason, JE | 1 |
| DeVita, VT | 1 |
| Canellos, GP | 1 |
| Kennedy, BJ | 1 |
| Verdaguer, J | 1 |
21 reviews available for hydroxyurea and Thrombocythemia
| Article | Year |
|---|---|
Thrombocytosis in children and adolescents-classification, diagnostic approach, and clinical management.
Topics: Adolescent; Adult; Age of Onset; Algorithms; Anticoagulants; Calreticulin; Child; Disease Management | 2021 |
Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
Topics: Aspirin; Calreticulin; Diagnosis, Differential; Disease Management; Humans; Hydroxyurea; Janus Kinas | 2015 |
Long-term management of thrombocytosis in essential thrombocythaemia.
Topics: Algorithms; Antineoplastic Agents; Aspirin; Female; Fibrinolytic Agents; Humans; Hydroxyurea; Interf | 2009 |
Comparison of the pharmacological mechanisms involved in the platelet lowering actions of anagrelide and hydroxyurea: a review.
Topics: Blood Platelets; Humans; Hydroxyurea; Platelet Aggregation Inhibitors; Quinazolines; Risk Assessment | 2002 |
Coexistence of chronic lymphocytic leukemia and essential thrombocythemia.
Topics: Aged; Chromosome Deletion; Chromosomes, Human, Pair 13; Clone Cells; Cytogenetic Analysis; Diagnosis | 2003 |
Thrombocytosis.
Topics: Aspirin; Clone Cells; Diagnosis, Differential; Humans; Hydroxyurea; Interferon-alpha; Plasmapheresis | 2004 |
Primary and secondary thrombocytosis in childhood.
Topics: Adolescent; Bacterial Infections; Blood Platelets; Child; Child, Preschool; Humans; Hydroxyurea; Inf | 2005 |
A critical review of anagrelide therapy in essential thrombocythemia and related disorders.
Topics: Clinical Trials as Topic; Humans; Hydroxyurea; Quinazolines; Thrombocythemia, Essential; Thrombocyto | 2005 |
Leg ulcers in elderly on hydroxyurea: a single center experience in Ph- myeloproliferative disorders and review of literature.
Topics: Age Factors; Aged; Aged, 80 and over; Female; Humans; Hydroxyurea; Leg Ulcer; Male; Myeloproliferati | 2006 |
Primary thrombocythemia: a current perspective.
Topics: Aspirin; Diagnosis, Differential; Humans; Hydroxyurea; Interferon Type I; Myeloproliferative Disorde | 1995 |
Hydroxyurea-induced fever: case report and review of the literature.
Topics: Fever; Humans; Hydroxyurea; Male; Middle Aged; Thrombocytosis | 1995 |
[Portal vein thrombosis associated with essential thrombocytosis. Clinical cases and review of the literature].
Topics: Adult; Aged; Diagnosis, Differential; Echocardiography, Doppler; Enteral Nutrition; Female; Humans; | 1996 |
Fever caused by hydroxyurea: a report of three cases and review of the literature.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Female; Fever; Humans; Hydroxyurea; Male; Middle Age | 1997 |
Treatment of essential thrombocythemia with special emphasis on leukemogenic risk.
Topics: Antineoplastic Agents; Humans; Hydroxyurea; Leukemia; Middle Aged; Risk Factors; Thrombocytosis; Thr | 1999 |
Leg ulcers in patients with myeloproliferative disorders: disease- or treatment-related?
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Female; Follow-Up Studies; Humans; Hydroxyurea; Leg | 2000 |
[Approaches to the treatment of essential thrombocythemia].
Topics: Humans; Hydroxyurea; Interferon-alpha; Thrombocytosis | 2000 |
Oral ulcers caused by hydroxyurea.
Topics: Aged; Anemia; Humans; Hydroxyurea; Male; Mouth Mucosa; Nucleic Acid Synthesis Inhibitors; Oral Ulcer | 2000 |
Diagnosis and treatment of thrombocythemia in myeloproliferative disorders.
Topics: Enzyme Inhibitors; Humans; Hydroxyurea; Immunologic Factors; Interferon-alpha; Polycythemia Vera; Qu | 2001 |
Therapeutic options for essential thrombocythemia and polycythemia vera.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Busulfan; Fibrinolytic Agen | 2002 |
Other secondary sequelae of treatments for myeloproliferative disorders.
Topics: Antineoplastic Agents; Fibrinolytic Agents; Humans; Hydroxyurea; Immunologic Factors; Interferon-alp | 2002 |
The clinical spectrum of thrombocytosis and thrombocythemia.
Topics: Blood Platelets; Cytokines; Hematopoiesis; Humans; Hydroxyurea; Interferon Type I; Megakaryocytes; P | 1991 |
8 trials available for hydroxyurea and Thrombocythemia
| Article | Year |
|---|---|
Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Female; | 2003 |
Anagrelide is effective in treating patients with hydroxyurea-resistant thrombocytosis in patients with chronic myeloid leukemia.
Topics: Adult; Drug Resistance; Female; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Positiv | 2005 |
Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes.
Topics: Adult; Antineoplastic Agents; Aspirin; Biopsy; Blood Cell Count; Drug Therapy, Combination; Hematolo | 2008 |
Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Female; Follow-Up Studies; Hemorrhage; Humans; Hydroxyurea; | 1995 |
The significance of thrombocytosis in patients with locally advanced cervical carcinoma: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Antineoplastic Agents; Cohort Studies; Combined Modality Therapy; Disease-Free Survival | 2000 |
Leukemogenic risk of hydroxyurea therapy as a single agent in polycythemia vera and essential thrombocythemia: N- and K-ras mutations and microsatellite instability in chromosomes 5 and 7 in 69 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cell Transformation, Neoplastic; Chromosomes, Human, Pai | 2002 |
Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Anagrelide Study Group.
Topics: Aged; Clinical Protocols; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; H | 1992 |
Hydroxyurea therapy in chronic myelogenous leukemia.
Topics: Bone Marrow; Bone Marrow Cells; Busulfan; Clinical Trials as Topic; Drug Resistance; Humans; Hydroxy | 1972 |
93 other studies available for hydroxyurea and Thrombocythemia
| Article | Year |
|---|---|
Moving toward disease modification in polycythemia vera.
Topics: Humans; Hydroxyurea; Interferon-alpha; Janus Kinase 2; Leukemia, Myeloid, Acute; Polycythemia Vera; | 2023 |
Limb gangrene: The first sign of essential thrombocythemia.
Topics: Aged, 80 and over; Amputation, Surgical; Aspirin; Female; Gangrene; Humans; Hydroxyurea; Leg; Platel | 2020 |
Hydroxyurea-induced squamous cell carcinoma.
Topics: Aged, 80 and over; Carcinoma, Squamous Cell; Female; Humans; Hydroxyurea; Neoplasms, Multiple Primar | 2021 |
Hydroxyurea Pharmacokinetics in Pediatric Patients After Total Pancreatectomy With Islet Autotransplantation.
Topics: Adolescent; Anemia, Sickle Cell; Child; Child, Preschool; Female; Humans; Hydroxyurea; Islets of Lan | 2021 |
Differential diagnostic and treatment difficulties in a patient with acquired von Willebrand syndrome.
Topics: Aged, 80 and over; Blood Transfusion; Enzyme Inhibitors; Hemorrhage; Humans; Hydroxyurea; Male; Thro | 2021 |
Successful replantation of 2 digits in a patient with thrombocytosis after splenectomy: A case report.
Topics: Adolescent; Amputation, Traumatic; Finger Injuries; Fingers; Humans; Hydroxyurea; Male; Platelet Cou | 2018 |
Subungual melanoma complicated by hydroxyurea-induced melanonychia with non-melanoma Hutchinson's sign.
Topics: Aged; Female; Humans; Hydroxyurea; Hyperpigmentation; Melanoma; Nail Diseases; Nucleic Acid Synthesi | 2018 |
Two cases of myeloproliferative neoplasm with a concurrent JAK2 (V617F) mutation and BCR/ABL translocation without chronic myelogenous leukemia phenotype acquisition during hydroxyurea treatment.
Topics: Adult; Alleles; Fusion Proteins, bcr-abl; Heterozygote; Humans; Hydroxyurea; Janus Kinase 2; Leukemi | 2013 |
Cyclical thrombocytosis, acquired von Willebrand syndrome and aggressive non-melanoma skin cancers are common in patients with Philadelphia-negative myeloproliferative neoplasms treated with hydroxyurea.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Hydroxyurea; Janus Kinase 2; Leukemia, Myeloid, Chro | 2014 |
Successful management of acute bleeding in essential thrombocythemia using automated cell separator.
Topics: Administration, Oral; Adolescent; Automation; Blood Platelets; Body Weight; Cell Separation; Female; | 2014 |
Melanonychia and mucocutaneous hyperpigmentation from hydroxyurea use for the treatment of essential thrombocytosis.
Topics: Female; Humans; Hydroxyurea; Hyperpigmentation; Middle Aged; Nail Diseases; Nails; Stroke; Thrombocy | 2014 |
Hydroxyurea-induced interstitial pneumonitis: case report and review of the literature.
Topics: Aged; Antineoplastic Agents; Female; Humans; Hydroxyurea; Lung Diseases, Interstitial; Respiratory I | 2014 |
Hydroxycarbamide-induced cutaneous ulceration with a difference.
Topics: Diagnosis, Differential; Drug Eruptions; Female; Hematinics; Humans; Hydroxyurea; Middle Aged; Prima | 2014 |
Ruxolitinib- but not fedratinib-induced extreme thrombocytosis: the combination therapy with hydroxyurea and ruxolitinib is effective in reducing platelet count and splenomegaly/constitutional symptoms.
Topics: Antisickling Agents; Humans; Hydroxyurea; Male; Middle Aged; Nitriles; Platelet Count; Pyrazoles; Py | 2015 |
Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
Topics: Aspirin; Calreticulin; Diagnosis, Differential; Erythropoietin; Humans; Hydroxyurea; Interferon-alph | 2017 |
The combined use of hydroxyurea and anagrelide allows satisfactory hematologic control in patients with chronic myeloproliferative disorders and thrombocytosis: a report on 13 patients with poor tolerance to hydroxyurea monotherapy.
Topics: Adult; Aged; Blood Platelets; Chronic Disease; Drug Therapy, Combination; Drug Tolerance; Female; He | 2008 |
Chronic subdural hygroma with thrombocythemia: first case report.
Topics: Aged; Chronic Disease; Craniocerebral Trauma; Enzyme Inhibitors; Humans; Hydroxyurea; Male; Subdural | 2009 |
Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antisickling Agents; Bone and Bones; Female; Humans; Hydroxy | 2010 |
Refractory anaemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T) with superimposed 5q-syndrome.
Topics: Aged; Anemia, Macrocytic; Anemia, Refractory; Anemia, Sideroblastic; Antineoplastic Agents; Bone Mar | 2010 |
Hydroxyurea-associated squamous dysplasia in a monozygotic twin.
Topics: Aged, 80 and over; Carcinoma, Squamous Cell; Diseases in Twins; Facial Dermatoses; Female; Hand Derm | 2011 |
Frequency and distribution of asymptomatic brain lesions in patients with β-thalassemia intermedia.
Topics: Adolescent; Adult; beta-Thalassemia; Blood Transfusion; Brain Diseases; Cerebrum; Child; Cohort Stud | 2012 |
Double, suicidal intoxication with hydroxycarbamide--a case report.
Topics: Adult; Complex Mixtures; Diazepam; Drug Overdose; Ethanol; Female; Humans; Hydroxyurea; Paroxetine; | 2012 |
Longitudinal melanonychia in a patient with essential thrombocytosis under treatment with hydroxyurea.
Topics: Aged; Diagnosis, Differential; Female; Humans; Hydroxyurea; Nail Diseases; Nucleic Acid Synthesis In | 2012 |
Myocardial infarction and primary thrombocytosis in a young man.
Topics: Adult; Antineoplastic Agents; Coronary Angiography; Electrocardiography; Fibrinolytic Agents; Humans | 2003 |
[What should follow a treatment for pruritus in thrombocytosis?].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Female; Histamine H1 Antagonists; Humans; Hydroxyure | 2003 |
Severe hypersensitivity pneumonitis associated with anagrelide.
Topics: Adrenal Cortex Hormones; Alveolitis, Extrinsic Allergic; Antineoplastic Agents; Drug Interactions; F | 2003 |
[Ulcers on the legs and feet: a seldom recognised side effect of hydroxyurea].
Topics: Aged; Antineoplastic Agents; Foot Ulcer; Humans; Hydroxyurea; Leg Ulcer; Leukemia, Myelogenous, Chro | 2003 |
[Hydroxyurea-induced pneumonitis].
Topics: Antineoplastic Agents; Diagnosis, Differential; Humans; Hydroxyurea; Male; Middle Aged; Pneumonia; P | 2003 |
Thrombocytosis.
Topics: Humans; Hydroxyurea; Platelet Aggregation Inhibitors; Quinazolines; Thrombocytosis | 2004 |
Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders.
Topics: Adult; Aged; Aged, 80 and over; Busulfan; Enzyme Inhibitors; Female; Humans; Hydroxyurea; Leukemia, | 2005 |
Philadelphia-chromosome positive thrombocythemia in a child.
Topics: Benzamides; Bone Marrow; Child; Female; Humans; Hydroxyurea; Imatinib Mesylate; Philadelphia Chromos | 2005 |
Der(8)t(1;8) in myeloblastic transformation of ET with hydroxyurea as the sole prior treatment.
Topics: Cell Transformation, Neoplastic; Chromosome Aberrations; Chromosomes, Human, Pair 1; Chromosomes, Hu | 2005 |
New approaches to the treatment of thrombocytosis.
Topics: Humans; Hydroxyurea; Interferon-alpha; Myeloproliferative Disorders; Platelet Count; Quinazolines; T | 2003 |
[Focal segmental glomerulosclerosis in a patient with polycythemia vera].
Topics: Aged; Disease Progression; Female; Glomerulosclerosis, Focal Segmental; Humans; Hydroxyurea; Nitroso | 2005 |
Childhood essential thrombocytosis.
Topics: Child, Preschool; Female; Humans; Hydroxyurea; Thrombocytosis | 2006 |
An unusual case of toe ulceration.
Topics: Adult; Aspirin; Erythropoietin; Fibrinolytic Agents; Foot Ulcer; Hematocrit; Humans; Hydroxyurea; Ma | 2006 |
A case of hydroxyurea-induced transverse melanonychia.
Topics: Adult; Female; Humans; Hydroxyurea; Nail Diseases; Pigmentation Disorders; Thrombocytosis; Vision Di | 2006 |
[Appearance of leg ulcers associated with intake of anagrelide].
Topics: Adult; Fibrinolytic Agents; Humans; Hydroxyurea; Leg Ulcer; Male; Quinazolines; Thrombocytosis | 2007 |
Cerebral venous sinus thrombosis associated with essential thrombocytosis in a pediatric patient.
Topics: Adolescent; Anticoagulants; Aspirin; Bone Marrow; Follow-Up Studies; Humans; Hydroxyurea; Magnetic R | 2007 |
Hydroxyurea-induced leg ulcers treated with a protease-modulating matrix.
Topics: Aged; Aged, 80 and over; Animals; Bandages, Hydrocolloid; Cattle; Cellulose, Oxidized; Collagen; Fem | 2007 |
Photo-induced granulomatous eruption by hydroxyurea.
Topics: Diagnosis, Differential; Drug Eruptions; Female; Humans; Hydroxyurea; Middle Aged; Photosensitivity | 2007 |
[Development of acute coronary syndrome in three patients with essential thrombocythemia or polycythemia vera].
Topics: Adult; Anticoagulants; Antisickling Agents; Aspirin; Coronary Angiography; Diagnosis, Differential; | 2008 |
[Essential thrombocythemia. Clinical, biological study and developmental study of 61 cases].
Topics: Busulfan; Female; Hematologic Tests; Humans; Hydroxyurea; Male; Middle Aged; Phosphorus Radioisotope | 1984 |
Neurologic manifestations of essential thrombocythemia.
Topics: Humans; Hydroxyurea; Neurologic Manifestations; Thrombocytosis | 1984 |
Hydroxyurea in essential thrombocytosis.
Topics: Aspirin; Follow-Up Studies; Humans; Hydroxyurea; Platelet Aggregation Inhibitors; Thrombocytosis; Th | 1995 |
Hydroxyurea in essential thrombocytosis.
Topics: Humans; Hydroxyurea; Thrombocytosis; Thrombosis | 1995 |
Hydroxyurea in essential thrombocytosis.
Topics: Data Interpretation, Statistical; Humans; Hydroxyurea; Multivariate Analysis; Recurrence; Thrombocyt | 1995 |
Myeloproliferative disorders in two New Jersey families.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; beta-Thalassemia; Carcinoma, Non-Small-Cell Lung; Female; | 1995 |
Survival and risk of leukaemia in polycythaemia vera and essential thrombocythaemia treated with oral radiophosphorus: are safer drugs available?
Topics: Administration, Oral; Aged; Busulfan; Female; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Leukemi | 1995 |
Acquired von Willebrand disease as a cause of recurrent mucocutaneous bleeding in primary thrombocythemia: relationship with platelet count.
Topics: Adult; Bleeding Time; Female; Hemorrhage; Humans; Hydroxyurea; Mucous Membrane; Platelet Count; Skin | 1994 |
[Essential thrombocythemia and pregnancy].
Topics: Aspirin; Female; Humans; Hydroxyurea; Pregnancy; Pregnancy Complications, Hematologic; Pregnancy Out | 1994 |
Hydroxyurea and lower leg ulcers.
Topics: Aged; Female; Humans; Hydroxyurea; Leg Ulcer; Male; Middle Aged; Polycythemia Vera; Primary Myelofib | 1993 |
Combined plateletpheresis and cytotoxic chemotherapy for symptomatic thrombocytosis in myeloproliferative disorders.
Topics: Adult; Aged; Aged, 80 and over; Busulfan; Combined Modality Therapy; Cytarabine; Drug Therapy, Combi | 1993 |
Hydroxyurea-induced nail pigmentation.
Topics: Aged; Enzyme Inhibitors; Female; Fingers; Humans; Hydroxyurea; Hyperpigmentation; Nail Diseases; Thr | 1996 |
Acute lymphoblastic leukemia in a case of essential thrombocythemia.
Topics: Aged; Antigens, CD; Blast Crisis; Bone Marrow; Female; Humans; Hydroxyurea; Lymphocyte Activation; P | 1996 |
The microvasculature in myeloproliferative disease. A study using retinal fluorescein angiography.
Topics: Adult; Aged; Aged, 80 and over; Allergens; Antineoplastic Agents; Arterial Occlusive Diseases; Aspir | 1996 |
Is treatment with hydroxyurea leukemogenic in patients with essential thrombocythemia? An analysis of three new cases of leukaemic transformation and review of the literature.
Topics: Aged; Antisickling Agents; Cell Transformation, Neoplastic; Chromosome Aberrations; Female; Humans; | 1997 |
[Essential thrombocythemia in pregnancy. A case report and general considerations].
Topics: Adult; Aspirin; Drug Therapy, Combination; Female; Humans; Hydroxyurea; Infant, Newborn; Male; Plate | 1997 |
Fever attributed to the use of hydroxyurea.
Topics: Aged; Antineoplastic Agents; Female; Fever; Humans; Hydroxyurea; Male; Recurrence; Thrombocytosis | 1997 |
Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion.
Topics: Adult; Aged; Antisickling Agents; Chromosomes, Human, Pair 17; Female; Gene Deletion; Humans; Hydrox | 1998 |
Early cutaneous lesions secondary to hydroxyurea therapy.
Topics: Aged; Humans; Hydroxyurea; Male; Skin Ulcer; Thrombocytosis; Time Factors | 1998 |
Multiple skin cancers associated with hydroxyurea therapy.
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Female; Humans; Hydroxyurea; Middle Aged; Neoplasms | 1998 |
Leg ulceration with associated thrombocytosis: healing of ulceration associated with treatment of the raised platelet count.
Topics: Antineoplastic Agents; Humans; Hydroxyurea; Leg Ulcer; Leukemia, Myelogenous, Chronic, BCR-ABL Posit | 1999 |
Hydroxyurea as a cause of drug fever in essential thrombocythaemia.
Topics: Aged; Aged, 80 and over; Antisickling Agents; Female; Fever; Humans; Hydroxyurea; Thrombocytosis | 1999 |
Hydroxyurea-induced leg ulcers: is macroerythrocytosis a pathogenic factor?
Topics: Animals; Dogs; Female; Humans; Hydroxyurea; Leg Ulcer; Middle Aged; Nucleic Acid Synthesis Inhibitor | 1999 |
Longitudinal melanonychia associated with hydroxyurea therapy in a patient with essential thrombocytosis.
Topics: Aged; Female; Humans; Hydroxyurea; Melanins; Melanosis; Nail Diseases; Thrombocytosis; Time Factors | 1999 |
Bilateral retinal vascular occlusive disease in essential thrombocythemia.
Topics: Diagnosis, Differential; Fluorescein Angiography; Fundus Oculi; Humans; Hydroxyurea; Male; Middle Ag | 1999 |
Hydroxyurea-induced cutaneous ulceration in older patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Female; Foot Ulcer; Humans; Hydroxyurea; Leukemia, M | 2000 |
Plasma erythropoietin in essential thrombocythaemia: at diagnosis and in response to myelosuppressive treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Erythropoietin; Female; Humans; Hydroxyurea; | 2000 |
Hydroxyurea induced skin ulceration in myeloproliferative disorders.
Topics: Aged; Female; Humans; Hydroxyurea; Male; Middle Aged; Myeloproliferative Disorders; Nucleic Acid Syn | 2000 |
Trisomy 14 with thrombocytosis and monocytosis.
Topics: Aclarubicin; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2000 |
Thrombocytosis--report of a case.
Topics: Aged; Antineoplastic Agents; Female; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Po | 2000 |
BCR-ABL positive essential thrombocythaemia: a variant of chronic myelogerous leukaemia or a distinct clinical entity: a special case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Marrow; Diagnosis, Diffe | 2000 |
Medical management of a large aortic thrombus in a young woman with essential thrombocythemia.
Topics: Aorta, Abdominal; Aortic Diseases; Aspirin; Biopsy, Needle; Drug Therapy, Combination; Female; Follo | 2001 |
[Chronic progressive polycythemia and thrombocytosis].
Topics: Aged; Combined Modality Therapy; Female; Humans; Hydroxyurea; Phlebotomy; Polycythemia Vera; Thrombo | 2001 |
Comparative genomic hybridization in polycythemia vera and essential thrombocytosis patients.
Topics: Aged; Aged, 80 and over; Chromosome Aberrations; Female; Humans; Hydroxyurea; Male; Middle Aged; Nuc | 2001 |
Aggressive, extensive, vasculitic leg ulceration associated with hydroxyurea therapy and a fatal outcome.
Topics: Aged; Cyclophosphamide; Fatal Outcome; Female; Foot Ulcer; Glucocorticoids; Humans; Hydroxyurea; Imm | 2001 |
Essential thrombocythemia--a cause of myocardial infarction in a young male.
Topics: Adult; Blood Chemical Analysis; Cardiotonic Agents; Electrocardiography; Follow-Up Studies; Heparin; | 2001 |
[Hydroxyurea-induced leg ulcers in patients with chronic myeloproliferative disorders].
Topics: Aged; Antineoplastic Agents; Drug Eruptions; Female; Humans; Hydroxyurea; Leg Ulcer; Leukemia, Myelo | 2001 |
Chronic myeloid leukaemia with marked thrombocytosis in a patient with thalassaemia major: complete haematological remission under the combination of hydroxyurea and anagrelide.
Topics: Adult; Antisickling Agents; beta-Thalassemia; Drug Therapy, Combination; Humans; Hydroxyurea; Leukem | 2002 |
Replication status in leukocytes of treated and untreated patients with polycythemia vera and essential thrombocytosis.
Topics: Adult; Aged; Antisickling Agents; Cell Count; Cell Division; DNA Replication; Female; Humans; Hydrox | 2002 |
Acute priapism in a patient with unstable hemoglobin Perth and Factor V Leiden under effective oral anticoagulant therapy.
Topics: Activated Protein C Resistance; Adult; Anticoagulants; Cell Adhesion; Erythrocyte Membrane; Etilefri | 2001 |
Cost-effectiveness considerations in the treatment of essential thrombocythemia.
Topics: Antineoplastic Agents; Cost-Benefit Analysis; Fibrinolytic Agents; Humans; Hydroxyurea; Immunologic | 2002 |
Hydroxyurea in the management of the hematologic complications of chronic granulocytic leukemia.
Topics: Busulfan; Humans; Hydroxyurea; Leukemia, Myeloid; Leukocyte Count; Leukocytosis; Mitobronitol; Splen | 1975 |
Treatment of basophilic leukemia in a dog.
Topics: Animals; Basophils; Bone Marrow; Bone Marrow Cells; Busulfan; Dog Diseases; Dogs; Erythrocyte Count; | 1975 |
Primary thrombocytosis and myocardial ischemic syndrome in a young woman.
Topics: Adult; Aspirin; Coronary Angiography; Coronary Disease; Electrocardiography; Female; Humans; Hydroxy | 1992 |
Megakaryocyte size and ploidy in thrombocytopenic or megakaryocytopenic mice.
Topics: Anemia; Animals; Blood Platelets; Hydroxyurea; Immune Sera; Megakaryocytes; Mice; Mice, Mutant Strai | 1990 |
Thrombocytosis associated with a myeloproliferative disorder in a dog.
Topics: Animals; Blood Platelets; Combined Modality Therapy; Dog Diseases; Dogs; Hydroxyurea; Male; Microsco | 1989 |
Decreased natural killer (NK) activity in patients with myeloproliferative disorders.
Topics: Bloodletting; Humans; Hydroxyurea; Interferon Type I; Interleukin-2; Killer Cells, Natural; Myelopro | 1989 |
Splenectomy in early chronic myeloid leukaemia: preliminary report on 37 cases.
Topics: Adolescent; Adult; Blood Cell Count; Blood Platelets; Cytarabine; Death; Drug Therapy, Combination; | 1974 |
[A new etiology of inflammatory livedo: thrombocytosis].
Topics: Arteritis; Busulfan; Diagnosis, Differential; Erythromelalgia; Female; Foot Dermatoses; Humans; Hydr | 1969 |
Thrombocytosis in chronic granulocytic leukemia: incidence and clinical significance.
Topics: Anemia; Azauridine; Blood Cell Count; Blood Platelets; Bone Marrow Examination; Busulfan; Cell Trans | 1974 |
[Inflammatory livedo and idiopathic thrombocythemia. Remarkable therapeutic action of hydroxyurea].
Topics: Humans; Hydroxyurea; Male; Middle Aged; Pigmentation Disorders; Skin Manifestations; Thrombocytosis | 1967 |